The collaboration is focused on the evaluation of the combination of InVivo’s proprietary PLGA-PLL-based Neuro-Spinal Scaffold for treatment of spinal cord injury with Q Therapeutics’ adult neural progenitor cells, including those from induced pluripotent stem cells (iPSCs).
The two companies will share their respective technologies to explore the potential pre-clinical safety, feasibility, and synergistic properties of the combined technologies for applications in the central nervous system, notes a media release from InVivo Therapeutics.
“We are excited about our research collaboration with Q Therapeutics, a leading developer of adult neural progenitor cell therapies to treat debilitating CNS disease and injury,” says Richard Toselli, MD, InVivo’s president and chief executive officer, in the release.
“Although InVivo remains very focused on and optimistic about the potential clinical benefit of the Neuro-Spinal Scaffold as a stand-alone technology, we believe this scientific partnership will allow both parties the opportunity to evaluate in parallel whether there is also a potential additive preclinical benefit of the combined technologies,” he adds.
[Source(s): InVivo Therapeutics Holdings Corp, Business Wire]